Brian J. Christmas

A CD40 Agonist and PD-1 Antagonist Antibody Reprogram the Microenvironment of Nonimmunogenic Tumors to Allow T-cell–Mediated Anticancer Activity

E. Jaffee, John-William Sidhom, E. R. Torres, 2019, Cancer Immunology Research.

Regulation of the tumor immune microenvironment and vascular normalization in TNBC murine models by a novel peptide

E. Jaffee, A. Popel, V. Stearns, 2020, Oncoimmunology.

Entinostat Converts Immune-Resistant Breast and Pancreatic Cancers into Checkpoint-Responsive Tumors by Reprogramming Tumor-Infiltrating MDSCs

E. Jaffee, Alexander C. Hopkins, Nilofer Azad, 2018, Cancer Immunology Research.

A feasibility study of combined epigenetic and vaccine therapy in advanced colorectal cancer with pharmacodynamic endpoint

G. Rosner, N. Ahuja, E. Jaffee, 2021, Clinical Epigenetics.

Phenotypic shifts of tumor associated macrophages and STAT3 mediated suppression of myeloid derived suppressor cells drive sensitization of HER2+ tumor immunity

Daria A. Gaykalova, E. Jaffee, E. Fertig, 2021, bioRxiv.

Entinostat decreases immune suppression to promote anti-tumor responses in a HER2+ breast tumor microenvironment.

Daria A. Gaykalova, E. Jaffee, Gaurav Sharma, 2022, Cancer immunology research.

Entinostat in combination with nivolumab for patients with advanced cholangiocarcinoma and pancreatic adenocarcinoma.

L. Cope, E. Jaffee, M. Baretti, 2018 .